Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 931Schizophrenia research and treatmentMental Health and PsychiatryFamily Caregiving in Mental Illness

The DOI matches its Crossref record; 52 of the 53 references it cites were found in a registry or an index.

Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis.

Abstract

Background Relapse prevention with antipsychotic drugs compared with placebo in patients with schizophrenia has not been sufficiently addressed by previous systematic reviews. We aimed to assess the association between such drugs and various outcomes in patients with schizophrenia to resolve controversial issues. Methods We searched the Cochrane Schizophrenia Group's specialised register for reports published before Nov 11, 2008; and PubMed, Embase, and ClinicalTrials.gov for those before June 8, 2011. We also contacted pharmaceutical companies and searched the reference lists of included studies and previous reviews. Randomised trials of patients with schizophrenia continued on or withdrawn from any antipsychotic drug regimen after stabilisation were eligible. Our primary outcome was relapse between 7 and 12 months. We also examined safety and various functional outcomes. We used the random effects model and verified results for the primary outcome with a fixed effects model. Heterogeneity was investigated with subgroup and meta-regression analyses. Findings We identified 116 suitable reports from 65 trials, with data for 6493 patients. Antipsychotic drugs significantly reduced relapse rates at 1 year (drugs 27%vs placebo 64%; risk ratio [RR] 0·40, 95% CI 0·33-0·49; number needed to treat to benefit [NNTB] 3, 95% CI 2-3). Fewer patients given antipsychotic drugs than placebo were readmitted (10%vs 26%; RR 0·38, 95% CI 0·27-0·55; NNTB 5, 4-9), but less than a third of relapse…

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(12)60239-6

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 53 references

Research works printed but not linked: 2

  1. Kane, 2003, Optimising pharmacologic treatment of psychotic disorders, J Clin Psychiatry, 64, 1
  2. Carpenter, 1990, Continuous versus targeted medication in schizophrenic outpatients: outcome results, Am J Psychiatry, 147, 1138

Cited by

See all 931

Metadata

Authors
Leucht, S., Tardy, M., Komossa, K., Heres, S., Kissling, W., Salanti, G., & Davis, J. M.
Affiliations
  • TUM Klinikum (DE)
  • University of Ioannina (GR)
  • University of Illinois Chicago (US)
Corresponding author
Leucht, Stefan
Venue
The Lancet
Publisher
Elsevier BV
Published
2012-06
Volume
379
Issue
9831
Pages
2063-2071
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2011675347
Cited by
931
References
53
Citations by year
2026: 56 · 2025: 67 · 2024: 62 · 2023: 59 · 2022: 74 · 2021: 80 · 2020: 81 · 2019: 90 · 2018: 57 · 2017: 66 · 2016: 64 · 2015: 55 · 2014: 61 · 2013: 35 · 2012: 23
FWCI
7.48
Type
journal article
Language
en
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
  • mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
Funders
  • European Research Council (IMMA 260559)
  • Bundesministerium für Bildung und Forschung (01KG0816 88166528)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Social Sciences › Arts and Humanities › Philosophy › Mental Health and Psychiatry
  • Social Sciences › Psychology › Clinical Psychology › Family Caregiving in Mental Illness
Keywords
antipsychotic drugs, schizophrenia, relapse prevention, placebo comparison, relapse rate, hospital readmission, quality of life, aggression, weight gain, movement disorders, antipsychotic adverse effects, functional outcome, employment, mortality, number needed to treat, subgroup analysis, meta-regression, heterogeneity, publication bias, risk of bias
MeSH terms
Humans, Patient Dropouts, Patient Readmission, Placebos, Research Design, Schizophrenia, Sensitivity and Specificity, Antipsychotic Agents, Randomized Controlled Trials as Topic, Secondary Prevention

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. https://app.cochat.ai/papers/10.1016/s0140-6736(12)60239-6
The paper
Leucht, S., Tardy, M., Komossa, K., Heres, S., Kissling, W., Salanti, G., & Davis, J. M. (2012). Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. The Lancet. https://doi.org/10.1016/s0140-6736(12)60239-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.